Zacks.com on MSN19h
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyUNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...
A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...
Acquired In-Process Research and Development expense: Acquired in-process research and development expense was $51.7 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback